{"id":"homonicotinic-acid","rwe":[{"pmid":"41906984","year":"2026","title":"Synergistic Buried Interface Engineering via Bisphosphonate-Anchored Co-Self-Assembled Monolayers for High-Performance Inverted Perovskite Solar Cells.","finding":"","journal":"ACS applied materials & interfaces","studyType":"Clinical Study"},{"pmid":"41906945","year":"2026","title":"Effectiveness and safety of treatment for heterozygous familial hypercholesterolaemia and multifactorial dyslipidaemia in children: an overview of systematic reviews.","finding":"","journal":"European journal of preventive cardiology","studyType":"Clinical Study"},{"pmid":"41906925","year":"2026","title":"Rhizobacteria-Induced Systemic Priming Against Fungal Pathogens Involves Hydroxycinnamic Acid Amides.","finding":"","journal":"Plant, cell & environment","studyType":"Clinical Study"},{"pmid":"41906918","year":"2026","title":"Electroactive Dual-Drug Hydrogel-PLA Conduit for Nerve Regeneration.","finding":"","journal":"Journal of biomedical materials research. Part B, Applied biomaterials","studyType":"Clinical Study"},{"pmid":"41906915","year":"2026","title":"Copper sulfide nanoparticles coated with Fe-EGCG networks for targeted MR imaging and chemo/photothermal/chemodynamic synergetic therapy of tumors.","finding":"","journal":"Biomaterials science","studyType":"Clinical Study"}],"tags":[{"label":"homonicotinic acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Hydroxycarboxylic acid receptor 2","category":"target"},{"label":"HCAR2","category":"gene"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"geriavit","offLabel":[],"synonyms":["geriavit","3-pyridine-acetic acid","3-pyridineacetic acid","3-pyridylacetic acid","piristerol","homonicotinic acid"],"timeline":[],"approvals":[],"brandName":"Geriavit","ecosystem":[],"mechanism":{"target":"Hydroxycarboxylic acid receptor 2","targets":[{"gene":"HCAR2","source":"DrugCentral","target":"Hydroxycarboxylic acid receptor 2","protein":"Hydroxycarboxylic acid receptor 2"}],"modality":"Small Molecule","drugClass":"homonicotinic acid","explanation":"Imagine your cells have locks on them, and Geriavit has a key that fits into one of those locks. When it binds, it can influence how the cell behaves, potentially leading to changes in how the body responds to certain conditions. However, the exact details of how this works are still being studied.","oneSentence":"Geriavit works by binding to the hydroxycarboxylic acid receptor 2, which is involved in various cellular processes.","technicalDetail":"Geriavit's mechanism of action involves the binding of its homonicotinic acid moiety to the hydroxycarboxylic acid receptor 2, which is a type of G protein-coupled receptor. This interaction can modulate downstream signaling pathways, influencing various cellular processes and potentially leading to therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3505","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=homonicotinic acid","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:54:11.161166","biosimilars":[],"competitors":[{"drugName":"dimethyl fumarate","drugSlug":"dimethyl-fumarate","fdaApproval":"2013-03-27","patentExpiry":"Nov 16, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"diroximel fumarate","drugSlug":"diroximel-fumarate","fdaApproval":"2019-10-29","patentExpiry":"Sep 20, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"lovastatin","drugSlug":"lovastatin","fdaApproval":"1987-08-31","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"nicotinamide","drugSlug":"nicotinamide","fdaApproval":"1953-02-20","relationship":"same-target"},{"drugName":"nicotinic acid","drugSlug":"nicotinic-acid","fdaApproval":"1957-07-24","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"homonicotinic acid","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dimethyl-fumarate","brandName":"dimethyl fumarate","genericName":"dimethyl fumarate","approvalYear":"2013","relationship":"same-target"},{"drugId":"diroximel-fumarate","brandName":"diroximel fumarate","genericName":"diroximel fumarate","approvalYear":"2019","relationship":"same-target"},{"drugId":"lovastatin","brandName":"lovastatin","genericName":"lovastatin","approvalYear":"1987","relationship":"same-target"},{"drugId":"nicotinamide","brandName":"nicotinamide","genericName":"nicotinamide","approvalYear":"1953","relationship":"same-target"},{"drugId":"nicotinic-acid","brandName":"nicotinic acid","genericName":"nicotinic acid","approvalYear":"1957","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"7UFO07435N","UMLSCUI":"C2934609","PUBCHEM_CID":"108","IUPHAR_LIGAND_ID":"1590"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2108151,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 30","pmid":"41906984","title":"Synergistic Buried Interface Engineering via Bisphosphonate-Anchored Co-Self-Assembled Monolayers for High-Performance Inverted Perovskite Solar Cells.","journal":"ACS applied materials & interfaces"},{"date":"2026 Mar 30","pmid":"41906945","title":"Effectiveness and safety of treatment for heterozygous familial hypercholesterolaemia and multifactorial dyslipidaemia in children: an overview of systematic reviews.","journal":"European journal of preventive cardiology"},{"date":"2026 Mar 30","pmid":"41906925","title":"Rhizobacteria-Induced Systemic Priming Against Fungal Pathogens Involves Hydroxycinnamic Acid Amides.","journal":"Plant, cell & environment"},{"date":"2026 Apr","pmid":"41906918","title":"Electroactive Dual-Drug Hydrogel-PLA Conduit for Nerve Regeneration.","journal":"Journal of biomedical materials research. Part B, Applied biomaterials"},{"date":"2026 Mar 30","pmid":"41906915","title":"Copper sulfide nanoparticles coated with Fe-EGCG networks for targeted MR imaging and chemo/photothermal/chemodynamic synergetic therapy of tumors.","journal":"Biomaterials science"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Geriavit, a homonicotinic acid, is a small molecule targeting the hydroxycarboxylic acid receptor 2. Its mechanism of action is not well-documented, and it is not FDA-approved for any indications. As a result, there is limited information available on its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand Geriavit's potential therapeutic applications and risks. Currently, it is unclear whether Geriavit is patented or available as a generic medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}